Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,121 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Does first-line treatment have prognostic impact for unresectable HCC?-Atezolizumab plus bevacizumab versus lenvatinib.
Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Kosaka H, Shibata H, Aoki T, Tanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Iijima H, Kaibori M, Hiasa Y, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Hiraoka A, et al. Among authors: nishimura t. Cancer Med. 2023 Jan;12(1):325-334. doi: 10.1002/cam4.4854. Epub 2022 Jun 3. Cancer Med. 2023. PMID: 35666040 Free PMC article.
Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma.
Tsuchiya K, Asahina Y, Matsuda S, Muraoka M, Nakata T, Suzuki Y, Tamaki N, Yasui Y, Suzuki S, Hosokawa T, Nishimura T, Ueda K, Kuzuya T, Nakanishi H, Itakura J, Takahashi Y, Kurosaki M, Enomoto N, Izumi N. Tsuchiya K, et al. Among authors: nishimura t. Cancer. 2014 Jan 15;120(2):229-37. doi: 10.1002/cncr.28384. Epub 2013 Oct 7. Cancer. 2014. PMID: 24122122 Free PMC article. Clinical Trial.
Prediction of development of hepatocellular carcinoma using a new scoring system involving virtual touch quantification in patients with chronic liver diseases.
Aoki T, Iijima H, Tada T, Kumada T, Nishimura T, Nakano C, Kishino K, Shimono Y, Yoh K, Takata R, Ishii A, Takashima T, Sakai Y, Aizawa N, Nishikawa H, Ikeda N, Iwata Y, Enomoto H, Hirota S, Fujimoto J, Nishiguchi S. Aoki T, et al. Among authors: nishimura t. J Gastroenterol. 2017 Jan;52(1):104-112. doi: 10.1007/s00535-016-1228-7. Epub 2016 Jun 15. J Gastroenterol. 2017. PMID: 27306373
Predictive factors in patients with hepatocellular carcinoma receiving sorafenib therapy using time-dependent receiver operating characteristic analysis.
Nishikawa H, Nishijima N, Enomoto H, Sakamoto A, Nasu A, Komekado H, Nishimura T, Kita R, Kimura T, Iijima H, Nishiguchi S, Osaki Y. Nishikawa H, et al. Among authors: nishimura t. J Cancer. 2017 Feb 10;8(3):378-387. doi: 10.7150/jca.16786. eCollection 2017. J Cancer. 2017. PMID: 28261338 Free PMC article.
Clinical utility of bioimpedance analysis in liver cirrhosis.
Nishikawa H, Enomoto H, Iwata Y, Nishimura T, Iijima H, Nishiguchi S. Nishikawa H, et al. Among authors: nishimura t. J Hepatobiliary Pancreat Sci. 2017 Jul;24(7):409-416. doi: 10.1002/jhbp.455. Epub 2017 May 3. J Hepatobiliary Pancreat Sci. 2017. PMID: 28371518
Implication of Psoas Muscle Index on Survival for Hepatocellular Carcinoma Undergoing Radiofrequency Ablation Therapy.
Yuri Y, Nishikawa H, Enomoto H, Ishii A, Iwata Y, Miyamoto Y, Ishii N, Hasegawa K, Nakano C, Nishimura T, Yoh K, Aizawa N, Sakai Y, Ikeda N, Takashima T, Takata R, Iijima H, Nishiguchi S. Yuri Y, et al. Among authors: nishimura t. J Cancer. 2017 Jun 1;8(9):1507-1516. doi: 10.7150/jca.19175. eCollection 2017. J Cancer. 2017. PMID: 28775769 Free PMC article.
5,121 results